LGNDLigand Pharmaceuticals Incorporated
$301.78+81% 1Y
$301.78
$166.7652 weeks$316.44
LGND in its own filings
LGND's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
761
Events found in the filings · across 2,284 filings · the record starts in 1994
- Hard flags
- 4
Hard flags
- Most recent filing
- Sep 24, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 13, 1994
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Restatement admitted (non-reliance)4 occurrences
- 2016-11-14
- Change in certifying accountant5 occurrences
- 2016-08-26
- Late periodic report9 occurrences
- 2016-11-09
- Delisting notice / listing-rule failure6 occurrences
- 2005-09-06
- Material impairmenthistorical
- 2010-06-15
- SEC comment-letter activity58 occurrences
- 2021-01-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 2, 2026Condensed Consolidated Financial Statements.Material event (exhibits only) · press release
- Aug 6, 2026Ligand Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 14, 2026On July 14, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), completed its previously announced merger pursuant to the terms of that certain Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated May 16, 2026 (as …Material agreement entered · Form 8-K
- Jun 25, 2026On June 25, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) completed its previously announced private offering of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an …Material agreement entered · Form 8-K
- Jun 22, 2026In connection with the Offering (as defined below), on June 22, 2026, Ligand Pharmaceuticals Incorporated (the “Company”), as borrower, entered into a Consent and Fourth Amendment to Credit Agreement (the “Fourth Amendment”) with certain of the Company’s subsidiaries, as Guarantors (as defined therein), the Lenders …Material agreement entered · Form 8-K
- Jun 9, 2026The 2026 Annual Meeting of the Stockholders of Ligand Pharmaceuticals Incorporated (the “Company”) was held on June 5, 2026 (the “Annual Meeting”)Director or officer change · Form 8-K
- May 18, 2026As previously disclosed, on April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Ligand, XOMA Royalty Corporation, a Nevada corporation (“XOMA Royalty”), and Flex Merger Sub, Inc., a Nevada …Material agreement entered · Form 8-K
- May 7, 2026Ligand Reports First Quarter 2026 Financial Results.Earnings release · press release
- Apr 30, 2026On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics …Material agreement terminated · Form 8-K
- Apr 27, 2026On April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Ligand, XOMA Royalty Corporation, a Nevada corporation (“XOMA Royalty”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…